#United States #cancer therapy #Karyopharm #XPOVIO #Newton

Karyopharm's Promising Outlook for 2026: Revenue Growth and Trial Expectations

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), known for its role in innovative cancer treatments, has shared optimistic projections regarding its financial performance and clinical trial results for 2026. The company has reported preliminary unaudited revenue for 2025, projecting approximately $145 million in total revenue, with $115 million expected from the net sales of their flagship product, XPOVIO® (selinexor). These figures indicate stable momentum for the company as it heads into a year filled with critical data readouts from ongoing clinical trials.

Key Highlights from 2025

In 2025, Karyopharm experienced consistent demand for XPOVIO, particularly in the competitive landscape of multiple myeloma treatments, where it accounted for about 60% of revenue generated in community settings. Notably, Karyopharm expanded global access for selinexor, achieving favorable reimbursement across several key markets, including Spain and China. These developments are indicative of Karyopharm's commitment to expanding its reach globally and improving patient accessibility to life-saving therapies.

Clinical Trials Set to Provide Major Insights

Karyopharm is on schedule to present top-line data from its Phase 3 clinical trial, known as the SENTRY trial, for the treatment of myelofibrosis in March 2026. This trial evaluates the efficacy of a once-weekly dose of selinexor in conjunction with ruxolitinib, a therapy already approved for myelofibrosis treatment. Positive outcomes from this trial could potentially redefine standard care practices in this rare blood cancer.

In tandem, the XPORT-EC-042 trial, which targets advanced endometrial cancer, is also set to produce top-line data by mid-2026. This trial investigates selinexor as a maintenance therapy following systemic treatment and is focused on a biomarker-driven patient population, representing a significant opportunity to enhance patient outcomes in this area.

Financial Investments and Strategic Directions

The company has undertaken strategic financing efforts to extend its cash runway, ensuring support for continued research and development beyond the anticipated clinical data readouts in 2026. As of December 31, 2025, Karyopharm reported approximately $64 million in cash and liquid assets, putting them in a strong position to fund operations into the second quarter of 2026 and beyond.

Looking to the Future

Karyopharm's aspirations for 2026 extend beyond immediate revenue and trial data. The company aims to solidify its foundation in the competitive market of multiple myeloma while actively preparing to launch new therapies if clinical trials yield positive results. With these promising statistics and plans, the next year could prove monumental for Karyopharm and the patients it serves.

As Karyopharm's clinical data approach the public domain, eyes will be on the company to see if it can fulfill its promises of transforming cancer treatment and improving survival rates through innovative therapies. We will continue to monitor their progress and provide updates on forthcoming study results as they become available.